Résumé
La littérature comporte un nombre limité de données relatives à l’histoire naturelle et l’épidémiologie du reflux gastroœsophagien (RGO). En revanche, les mécanismes pathogéniques de l’œsophagite sont mieux connus mais les connaissances demeurent encore fragmentaires.
Entre 12 et 36 % de la population présentent du pyrosis, 40 à 60 % des patients souffrant de pyrosis présentent une œsophagite reconnue par l’endoscopie, et parmi les patients porteurs de lésions d’œsophagite endoscopique, 8 à 10 % ont un œsophage de Barrett. Certains patients souffrant de reflux gastro-œsophagien présentent seulement des signes histologiques de maladie par reflux, en l’absence d’anomalies endoscopiques. Chez la majorité des patients souffrant d’une maladie par reflux décelée à l’endoscopie ou par l’histologie, on constate des récidives systématiques et des rechutes chroniques des symptômes, entraînant une prise en charge thérapeutique à long terme. L’histoire naturelle de la pathologie du reflux et de l’œsophagite a été modifiée dans le sens favorable depuis l’utilisation des antagonistes H2 à l’histamine, de l’Omeprazole et des médicaments prokinétiques. Grâce à une compréhension améliorée des mécanismes pathogéniques de l’œsophagite, le traitement de cette affection chronique va vraisemblablement s’améliorer et modifier par conséquent, l’histoire naturelle du reflux gastro-œsophagien.
Summary
There are limited data in the literature regarding the natural history and epidemiology of gastroesophageal reflux disease (GERD). Much is known about the pathomechanisms of esophagitis, but even more remains to be learned.
Twelve to thirty-six percent of people experience heartburn, 40–60 % of patients with heartburn have endoscopic evidence of esophagitis, and 8–10 % of patients with endoscopic esophagitis have Barrett’s esophagitis. Some patients with gastroesophageal reflux disease have only histological evidence of GERD, with normal endoscopic findings. In the majority of patients with endoscopic or histologic GERD, it is a symptomatically recurrent and chronic relapsing process requiring longterm therapy. The natural history of GERD and esophagitis is being altered to a more favorable status with the use of Histamine-2 antagonists and Omeprazole as well as prokinetic agents. With increased understanding of the pathomechanisms of esophagitis, treatment of this chronic disease is likely to improve and result in further modifications in the natural history of gastroesophageal reflux disease.
Références
ALLISON P.R. — Reflux œsophagitis; its pathology and treatment.Scan. J. Thor. Cardiovasc. Surg., 1972,6, 318–322.
BORRIE J., GOLDWATER L. — Columnar cell-lined esophagus: assessment of etiology and treatment. A 22 year experience.J. thorac. Cardiovasc. Surg., 1976,71, 825–834.
GLISE H. — Healing, relapse rates and prophylaxis of reflux esophagitis.Scan. J. Gastroenterol., 1989,24 (suppl. 156), 57–64.
GOLDMAN M.C., BECKMAN R.C. — Barrett syndrome: case report with discussion about concepts of pathogenesis.Gastro., 1960,39, 104–110.
GRAHAM D.Y., SMITH J.L., PATTERSON D.J. — Why do apparently healthy people use antacid tablets?Am. J. Gastro., 1983,78, 257–260.
HANDS L.J., DENNISON A.R., PAPAVRAMIDIS S., McINTYRE R.L., BISHOP H., KETTLEWELL M.G. — The natural history of peptic oesophageal strictures treated by dilatation and antireflux therapy alone.Ann. Royal College Surg. Engl., 1989,71, 306–310.
HEADING R.C. — Epidemiology of œsophageal reflux disease.Scan. J. Gastroenterol., 1989,24 (suppl. 168), 33–37.
Heartburn across America : a Gallup organization national survey. Princeton, N.J., Gallup Organization, 1988.
HELM J.F., DODDS W.J., PELC L.R. et al. — Effect of esophageal emptying and saliva on clearance of acid from the esophagus.NRJM, 1984,310, 284–288.
HETZEL D.P., SAROSIEK J., PEURA D.A., PIASCIK R., FENG T., McCALLUM R.W. — Mucus secretion by human esophageal mucosa : the effect of challenge with acid and pepsin.Gastro., 1992,102, A83 (abstract).
HETZEL D.J., DENT J., REED W.D. et al. — Healing and relapse of severe peptic esophagitis after treatment with omeprazole.Gastro., 1988,95, 903–912.
HOLLOWAY R.H., DENT J. — Pathophysiology of gastroesophageal reflux.Gastro. Clinics No. America., 1990,19, 517–535.
KINGSNORTH A.W., SMITH P., RICHARDS R.C. — Parotid salivary epidermal growth factor levels in human reflux esophagitis and PUD.Gastro., 1989,96, A257 (abstract).
LIEBERMAN D.A. — Medical therapy for chronic reflux esophagitis: long-term follow-up.Arch. Intern. Med., 1987,147, 1717–1720.
MOLD J.W., REED L.E., DAVIS A.B., ALLEN M.L., DECKTOR D.L., ROBINSON M. — Prevalence of gastrœsophageal reflux in elderly patients in a primary care setting.Am. J. Gastro., 1991,86, 965–970.
MOSSBERG S.M. — The columnar-lined esophagus (Barrett syndrome): an aquired condition ?Gastro., 1966,50, 671–676.
NEBEL O.T., FORNES M.F., CASTELL D.O. — Symptomatic gastrœsophageal reflux: incidence and precipitating factors.Dig. Dis. Sci., 1976,21, 953–956.
ORLANDO R.C. — Reflux esophagitis. In Yamada T et al.: Textbook of Gastroenterology. New York, Lippincott, 1991.
PACE F., SANTALUCIA F., BIANCHI PORRO G. — Natural history of gastroesophageal reflux disease without oesophagitis.Gut, 1991,32, 845–848.
PALMER E.D. — The hiatus hernia-esophagitis-esophageal stricture complex: twenty year prospective study.Am. J. Medicine, 1968,44, 566–577.
PATTERSON D.J., GRAHAM D.Y., SMITH J.L., SCHWARTZ J.T., ALPERT E.L., LANZA F.L., CAIN G.D. — Natural history of benign esophageal stricture treated by dilatation.Gastro., 1983,85, 346–350.
PHILLIPS R.W., WONG R.K.H. — Barrett’s esophagus: natural history, incidence, etiology, and complications.Gastro. Clinics No. Amer., 1991,20, 791–816.
REX J.C., ANDERSEN H.A., BARTHOLOMEW L.G., CAIN J.C. — Esophageal hiatal hernia: a 10-year study of medically treated cases.JAMA, 1961,178, 117–120.
RICHTER J.E. — Surgery for reflux disease: reflections of a gastroenterologist.NEJM, 1992,326, 825–827.
SALTZMAN M., BARWICK K., McCALLUM R.W. — Progression of cimetidine-treated reflux esophagitis to a Barrett’s stricture.Dig. Dis. Sci., 1982,27, 181–186.
SAROSIEK J., HETZEL D.P., PEURA D.A., PIASCIK R., FENG T., MCCALLUM R.W. — Human esophageal bicarbonate : the rate of secretion during perfusion with NaCl, HCl, and HCl/Pepsin solution.Gastro, 1992,102, A158 (abstract).
SCHNELL T., SONTAG S., WANNER J., CHINTAM R., CHEJFEC G., O’CONNELL S., MORONI B. — Endoscopic screening for Barrett’s esophagus (BE), esophageal adenocarcinoma (AdCa) and other mucosal changes in ambulatory subjects with symptomatic gastroesophageal reflux (GER).Gastro, 1985,88, 1576 (abstract).
SPECHLER S.J., GOYAL R.K. — Barrett’s esophagus.NEJM, 1986,315, 363–371.
STALNIKOWICZ-DARVASI R. — H2 antagonists in the treatment of reflux esophagitis: a critical analysis.Am. J. Gastro., 1989,84, 245–248.
TALLEY N.J., ZINSMEISTER A.R., SCHLECK C., MELTON L.J. — Natural history of gastroesophageal reflux : a population-based study.Gastro., 1992,102, A28 (abstract).
TREEM W.R., DAVIS P.M., HYAMS J.S. — Gastroesophageal reflux in the older child: presentation, response to treatment and long-term follow-up.Clin. Pediatrics, 1991,30, 435–440.
TUOHY C.D., ALLEN V., SAMPLINER R.E., AICKEN M., GAREWAL H. — Can symptoms alone differentiate patients with Barrett’s esophagus from patients with gastroesophageal reflux disease lacking Barrett’s ?Gastro, 1990,98, A141 (abstract).
WIENBECK M., BARNERT J. — Epidemiology of reflux disease and reflux esophagitis.Scan. J. Gastroenterol., 1989,24 (suppl. 156), 7–13.
WINTERS C., SPURLING T.J., CHOBANIAN S.J., CURTIS D.J., ESPOSITO R.L., HACKER J.F., JOHNSON D.A., CRUESS D.F., COTELINGAM J.D., GURNEY M.S., CATTAU E.L. — Barrett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease.Gastro, 1987,92, 118–124.
Author information
Authors and Affiliations
About this article
Cite this article
Hetzel, D.P., McCallum, R.W. L’histoire naturelle du reflux gastro-œsophagien. Acta Endosc 23, 73–81 (1993). https://doi.org/10.1007/BF02968617
Issue Date:
DOI: https://doi.org/10.1007/BF02968617